Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
627
datasets available to search
ShareScore release 0.9.0
Dataset results
627 results for “Active Participation”
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 12 Anorexia Nervosa Patients to 12 Controls-Figure 1: sLORETA imaging results of Resting State EEG Supra-Threshold Voxels in both the Parahippocampal (limbic) and Fusiform (temporal) Gyri illustrating decreased neuronal activity in the Anorexia Nervosa patients relative to Control participants
<p>The findings of the sLORETA analysis indicated that, the difference is statistically<br> significant (p=0.03) using a one-tailed t-test: Anorexia > Controls. The brains of the patients with<br> Anorexia Nervosa illustrated decreased neuronal activity in the Left Fusiform Gyrus and the Left<br> Parahippocampal Gyrus (p=0.03) in the resting-state brains when Anorexia Patients were sitting for<br> 3min, as compared to the Controls sitting for 3minutes.</p>
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants
ClinicalTrials.gov study NCT03319953. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
ClinicalTrials.gov study NCT03345836. IPD Sharing: YES. Countries: 48. Publications: 7.
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
ClinicalTrials.gov study NCT02819635. IPD Sharing: YES. Countries: 46. Publications: 13.
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheum
ClinicalTrials.gov study NCT03675308. IPD Sharing: YES. Countries: 39. Publications: 9.
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
ClinicalTrials.gov study NCT02294227. IPD Sharing: UNDECIDED. Countries: 13. Publications: 3.
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
ClinicalTrials.gov study NCT02721966. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
ClinicalTrials.gov study NCT03787095. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
ClinicalTrials.gov study NCT03671148. IPD Sharing: YES. Countries: 25. Publications: 9.
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov study NCT03653026. IPD Sharing: YES. Countries: 44. Publications: 9.
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
ClinicalTrials.gov study NCT03104413. IPD Sharing: YES. Countries: 43. Publications: 5.
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov study NCT03105128. IPD Sharing: YES. Countries: 44. Publications: 7.
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
ClinicalTrials.gov study NCT02159053. IPD Sharing: UNDECIDED. Countries: 19. Publications: 6.
shemakes activities: record of activities and participation in the learning paths and innovation services.
<p><strong>Shemakes record of activities and participation dataset</strong> contains the number of participants for each event or activity during the project duration collected mainly from the WP2 learning paths and WP3 innovation services, which are the WPs with a high amount of activities and events related to the shemakes development. It does not contain personal or sensitive data, as it is focused on the event's typology. Participants are aggregated per activity. Besides, the dataset includes information about 1) the country where the activity is carried out and 2) it mentions the type of activity and its title. The data about the participants comprises the number of females, whether the females were adults or minors and the percentage of female participants.</p>
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov study NCT02877134. IPD Sharing: Not stated. Countries: 14. Publications: 2.
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
ClinicalTrials.gov study NCT04292730. IPD Sharing: YES. Countries: 15. Publications: 3.
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
ClinicalTrials.gov study NCT02920021. IPD Sharing: NO. Countries: 1. Publications: 1.
TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
ClinicalTrials.gov study NCT00449644. IPD Sharing: Not stated. Countries: 8. Publications: 5.
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT04294667. IPD Sharing: YES. Countries: 25. Publications: 0.
A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
ClinicalTrials.gov study NCT03792672. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.